Do analysts recommend VTSI or DFNS?

VirTra currently has a consensus price target of $5.00, indicating a potential upside of 88.68%. Given VirTra's higher probable upside, analysts clearly believe VirTra is more favorable than Nukkleus. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VirTra 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nukkleus 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, VTSI or DFNS?

Nukkleus has lower revenue, but higher earnings than VirTra. VirTra is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VirTra $22.40M 1.34 $260K -$0.26 N/A Nukkleus $5.91M 1.62 $78.55M -$397.10 N/A

Is VTSI or DFNS more profitable?

Nukkleus has a net margin of 0.00% compared to VirTra's net margin of -17.04%. Nukkleus' return on equity of 0.00% beat VirTra's return on equity. Company Net Margins Return on Equity Return on Assets VirTra -17.04% -6.59% -4.57% Nukkleus N/A N/A -26.92%

Do analysts recommend ZENA or DFNS?

ZenaTech presently has a consensus target price of $4.50, indicating a potential upside of 312.84%. Given ZenaTech's higher possible upside, analysts plainly believe ZenaTech is more favorable than Nukkleus. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZenaTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Nukkleus 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, ZENA or DFNS?

Nukkleus has lower revenue, but higher earnings than ZenaTech. ZenaTech is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZenaTech $9.24M 2.65 -$32.36M -$1.48 N/A Nukkleus $5.91M 1.62 $78.55M -$397.10 N/A

Is ZENA or DFNS more profitable?

Nukkleus has a net margin of 0.00% compared to ZenaTech's net margin of -306.35%. Nukkleus' return on equity of 0.00% beat ZenaTech's return on equity. Company Net Margins Return on Equity Return on Assets ZenaTech -306.35% -3,081.41% -76.55% Nukkleus N/A N/A -26.92%

Do analysts recommend XTIA or DFNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTI Aerospace 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Nukkleus 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is XTIA or DFNS more profitable?

Nukkleus has a net margin of 0.00% compared to XTI Aerospace's net margin of -171.13%. Nukkleus' return on equity of 0.00% beat XTI Aerospace's return on equity. Company Net Margins Return on Equity Return on Assets XTI Aerospace -171.13% -2,044.78% -105.02% Nukkleus N/A N/A -26.92%

Do analysts rate DFNS or EURK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nukkleus 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Eureka Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, DFNS or EURK?

Nukkleus has higher revenue and earnings than Eureka Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nukkleus $5.91M 1.62 $78.55M -$397.10 N/A Eureka Acquisition N/A N/A N/A N/A N/A

Is DFNS or EURK more profitable?

Company Net Margins Return on Equity Return on Assets Nukkleus N/A N/A -26.92% Eureka Acquisition N/A N/A N/A

Do analysts rate QUCY or DFNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.25 Nukkleus 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, QUCY or DFNS?

Nukkleus has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $537.08K 28.12 -$16.21M -$10.37 N/A Nukkleus $5.91M 1.62 $78.55M -$397.10 N/A

Is QUCY or DFNS more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Nukkleus N/A N/A -26.92%

Nukkleus (DFNS) Competitors

$5.67 -0.08 (-1.39%)

As of 08:52 AM Eastern

Compare

DFNS vs. VTSI, ZENA, XTIA, EURK, and QUCY

Should you buy Nukkleus stock or one of its competitors? Nukkleus's main competitors and comparable companies include VirTra (VTSI), ZenaTech (ZENA), XTI Aerospace (XTIA), Eureka Acquisition (EURK), and Mainz Biomed (QUCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "aerospace & defense" industry.

How does Nukkleus compare to VirTra?

VirTra (NASDAQ:VTSI) and Nukkleus (NASDAQ:DFNS) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Nukkleus has a net margin of 0.00% compared to VirTra's net margin of -17.04%. Nukkleus' return on equity of 0.00% beat VirTra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VirTra	-17.04%	-6.59%	-4.57%
Nukkleus	N/A	N/A	-26.92%

14.7% of VirTra shares are owned by institutional investors. Comparatively, 12.5% of Nukkleus shares are owned by institutional investors. 3.5% of VirTra shares are owned by company insiders. Comparatively, 11.1% of Nukkleus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, VirTra had 3 more articles in the media than Nukkleus. MarketBeat recorded 4 mentions for VirTra and 1 mentions for Nukkleus. Nukkleus' average media sentiment score of 1.79 beat VirTra's score of 0.72 indicating that Nukkleus is being referred to more favorably in the news media.

Company	Overall Sentiment
VirTra	Positive
Nukkleus	Very Positive

VirTra currently has a consensus price target of $5.00, indicating a potential upside of 88.68%. Given VirTra's higher probable upside, analysts clearly believe VirTra is more favorable than Nukkleus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VirTra	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nukkleus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Nukkleus has lower revenue, but higher earnings than VirTra. VirTra is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VirTra	$22.40M	1.34	$260K	-$0.26	N/A
Nukkleus	$5.91M	1.62	$78.55M	-$397.10	N/A

VirTra has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Nukkleus has a beta of -6.05, meaning that its stock price is 705% less volatile than the broader market.

Summary

Nukkleus beats VirTra on 9 of the 17 factors compared between the two stocks.

How does Nukkleus compare to ZenaTech?

ZenaTech (NASDAQ:ZENA) and Nukkleus (NASDAQ:DFNS) are both small-cap industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

12.5% of Nukkleus shares are owned by institutional investors. 11.1% of Nukkleus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nukkleus has a net margin of 0.00% compared to ZenaTech's net margin of -306.35%. Nukkleus' return on equity of 0.00% beat ZenaTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZenaTech	-306.35%	-3,081.41%	-76.55%
Nukkleus	N/A	N/A	-26.92%

ZenaTech has a beta of 7.34, meaning that its stock price is 634% more volatile than the broader market. Comparatively, Nukkleus has a beta of -6.05, meaning that its stock price is 705% less volatile than the broader market.

In the previous week, ZenaTech had 13 more articles in the media than Nukkleus. MarketBeat recorded 14 mentions for ZenaTech and 1 mentions for Nukkleus. Nukkleus' average media sentiment score of 1.79 beat ZenaTech's score of 0.75 indicating that Nukkleus is being referred to more favorably in the news media.

Company	Overall Sentiment
ZenaTech	Positive
Nukkleus	Very Positive

Nukkleus has lower revenue, but higher earnings than ZenaTech. ZenaTech is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZenaTech	$9.24M	2.65	-$32.36M	-$1.48	N/A
Nukkleus	$5.91M	1.62	$78.55M	-$397.10	N/A

ZenaTech presently has a consensus target price of $4.50, indicating a potential upside of 312.84%. Given ZenaTech's higher possible upside, analysts plainly believe ZenaTech is more favorable than Nukkleus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZenaTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nukkleus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Nukkleus beats ZenaTech on 10 of the 17 factors compared between the two stocks.

How does Nukkleus compare to XTI Aerospace?

XTI Aerospace (NASDAQ:XTIA) and Nukkleus (NASDAQ:DFNS) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTI Aerospace	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nukkleus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

XTI Aerospace has a beta of 4.85, indicating that its stock price is 385% more volatile than the broader market. Comparatively, Nukkleus has a beta of -6.05, indicating that its stock price is 705% less volatile than the broader market.

11.7% of XTI Aerospace shares are owned by institutional investors. Comparatively, 12.5% of Nukkleus shares are owned by institutional investors. 7.4% of XTI Aerospace shares are owned by insiders. Comparatively, 11.1% of Nukkleus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nukkleus has a net margin of 0.00% compared to XTI Aerospace's net margin of -171.13%. Nukkleus' return on equity of 0.00% beat XTI Aerospace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTI Aerospace	-171.13%	-2,044.78%	-105.02%
Nukkleus	N/A	N/A	-26.92%

In the previous week, XTI Aerospace had 7 more articles in the media than Nukkleus. MarketBeat recorded 8 mentions for XTI Aerospace and 1 mentions for Nukkleus. Nukkleus' average media sentiment score of 1.79 beat XTI Aerospace's score of 0.20 indicating that Nukkleus is being referred to more favorably in the news media.

Company	Overall Sentiment
XTI Aerospace	Neutral
Nukkleus	Very Positive

Nukkleus has lower revenue, but higher earnings than XTI Aerospace. XTI Aerospace is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTI Aerospace	$22.49M	1.47	-$68.76M	-$5.20	N/A
Nukkleus	$5.91M	1.62	$78.55M	-$397.10	N/A

Summary

Nukkleus beats XTI Aerospace on 9 of the 13 factors compared between the two stocks.

How does Nukkleus compare to Eureka Acquisition?

Nukkleus (NASDAQ:DFNS) and Eureka Acquisition (NASDAQ:EURK) are both small-cap industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Nukkleus has higher revenue and earnings than Eureka Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nukkleus	$5.91M	1.62	$78.55M	-$397.10	N/A
Eureka Acquisition	N/A	N/A	N/A	N/A	N/A

12.5% of Nukkleus shares are owned by institutional investors. 11.1% of Nukkleus shares are owned by company insiders. Comparatively, 34.5% of Eureka Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nukkleus has a beta of -6.05, suggesting that its stock price is 705% less volatile than the broader market. Comparatively, Eureka Acquisition has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Nukkleus	N/A	N/A	-26.92%
Eureka Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nukkleus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Eureka Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eureka Acquisition had 1 more articles in the media than Nukkleus. MarketBeat recorded 2 mentions for Eureka Acquisition and 1 mentions for Nukkleus. Nukkleus' average media sentiment score of 1.79 beat Eureka Acquisition's score of 0.41 indicating that Nukkleus is being referred to more favorably in the media.

Company	Overall Sentiment
Nukkleus	Very Positive
Eureka Acquisition	Neutral

Summary

Nukkleus beats Eureka Acquisition on 5 of the 9 factors compared between the two stocks.

How does Nukkleus compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and Nukkleus (NASDAQ:DFNS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Nukkleus has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Nukkleus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	28.12	-$16.21M	-$10.37	N/A
Nukkleus	$5.91M	1.62	$78.55M	-$397.10	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Nukkleus	N/A	N/A	-26.92%

In the previous week, Mainz Biomed and Mainz Biomed both had 1 articles in the media. Mainz Biomed's average media sentiment score of 1.79 equaled Nukkleus'average media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Very Positive
Nukkleus	Very Positive

12.5% of Nukkleus shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by insiders. Comparatively, 11.1% of Nukkleus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mainz Biomed has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Nukkleus has a beta of -6.05, indicating that its stock price is 705% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Nukkleus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Nukkleus beats Mainz Biomed on 6 of the 10 factors compared between the two stocks.

Get Nukkleus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFNS vs. The Competition

Export

Metric	Nukkleus	Aerospace & Defense Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$10M	$20.16B	$10.21B	$13.28B
Dividend Yield	N/A	1.71%	96.64%	20.73%
P/E Ratio	-0.01	36.03	26.64	25.82
Price / Sales	1.62	120.47	273.71	104.95
Price / Cash	0.01	25.17	23.92	36.12
Price / Book	-0.06	6.90	4.74	6.10
Net Income	$78.55M	$563.23M	$614.62M	$380.59M
7 Day Performance	-14.18%	-4.06%	-1.40%	-2.04%
1 Month Performance	-40.04%	-8.15%	-2.91%	-4.24%
1 Year Performance	-99.56%	-7.28%	2.06%	-1.55%

Nukkleus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFNS Nukkleus	1.3224 of 5 stars	$5.67 -1.4%	N/A	-99.4%	$9.41M	$5.91M	N/A	12	News Coverage Positive News
VTSI VirTra	3.8496 of 5 stars	$2.76 -2.8%	$5.00 +81.2%	-54.5%	$31.24M	$17.50M	N/A	94	Gap Up
ZENA ZenaTech	2.5366 of 5 stars	$1.30 +1.6%	$4.50 +246.2%	-81.6%	$29.25M	$9.24M	N/A	17
XTIA XTI Aerospace	0.4506 of 5 stars	$0.72 -1.9%	N/A	-40.2%	$28.38M	$50.19M	N/A	12
EURK Eureka Acquisition	0.6184 of 5 stars	$11.57 +0.2%	N/A	+7.0%	$25.11M	N/A	N/A	N/A	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFNS) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nukkleus (DFNS) Competitors

DFNS vs. VTSI, ZENA, XTIA, EURK, and QUCY

How does Nukkleus compare to VirTra?

Summary

How does Nukkleus compare to ZenaTech?

Summary

How does Nukkleus compare to XTI Aerospace?

Summary

How does Nukkleus compare to Eureka Acquisition?

Summary

How does Nukkleus compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFNS vs. The Competition

Nukkleus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nukkleus (DFNS) Competitors

DFNS vs. VTSI, ZENA, XTIA, EURK, and QUCY

How does Nukkleus compare to VirTra?

Is VTSI or DFNS more profitable?

Do insiders and institutionals believe in VTSI or DFNS?

Does the media prefer VTSI or DFNS?

Do analysts recommend VTSI or DFNS?

Which has higher valuation and earnings, VTSI or DFNS?

Which has more risk & volatility, VTSI or DFNS?

Summary

How does Nukkleus compare to ZenaTech?

Do institutionals & insiders believe in ZENA or DFNS?

Is ZENA or DFNS more profitable?

Which has more risk and volatility, ZENA or DFNS?

Does the media prefer ZENA or DFNS?

Which has preferable earnings & valuation, ZENA or DFNS?

Do analysts recommend ZENA or DFNS?

Summary

How does Nukkleus compare to XTI Aerospace?

Do analysts recommend XTIA or DFNS?

Which has more volatility and risk, XTIA or DFNS?

Do insiders & institutionals have more ownership in XTIA or DFNS?

Is XTIA or DFNS more profitable?

Does the media refer more to XTIA or DFNS?

Which has higher earnings and valuation, XTIA or DFNS?

Summary

How does Nukkleus compare to Eureka Acquisition?

Which has higher earnings and valuation, DFNS or EURK?

Do institutionals and insiders hold more shares of DFNS or EURK?

Which has more risk and volatility, DFNS or EURK?

Is DFNS or EURK more profitable?

Do analysts rate DFNS or EURK?

Does the media favor DFNS or EURK?

Summary

How does Nukkleus compare to Mainz Biomed?

Which has stronger earnings & valuation, QUCY or DFNS?

Is QUCY or DFNS more profitable?

Does the media prefer QUCY or DFNS?

Do institutionals & insiders believe in QUCY or DFNS?

Which has more volatility and risk, QUCY or DFNS?

Do analysts rate QUCY or DFNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFNS vs. The Competition

Nukkleus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools